



# INSTITUTIONAL BIOSAFETY COMMITTEE

---

UNIVERSITY *of* WASHINGTON

## Meeting Minutes

**Date:** Wednesday, April 14, 2021

**Time:** 10:00 AM – 10:30 AM

**Location:** Zoom

**Members Present:**

1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
3. Lesley Decker, Environmental Health & Safety (*Biosafety Officer*)
4. Garry Hamilton (*Community Member*)
5. David Koelle, Allergy and Infectious Diseases
6. Stephen Libby, Laboratory Medicine (*IBC Chair*)
7. Jason Smith, Microbiology (*IBC Vice Chair*)
8. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

### Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:01 a.m. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **SUBCOMMITTEE REPORTS:**
  - a. Veessler, David, change, *Expression of recombinant proteins using mammalian cell lines*
    - Four members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
    - This BUA change adds work with SARS-CoV-2 and human and non-human primate materials in the SLU 3.1 BSL3 facility. The aim of this work is to guide the design of the next generation of vaccines that are more resilient to antigenic drift as well as to sarbecovirus genetic diversity.
    - Live virus neutralization assays with purified antibodies, human convalescent plasma, and vaccine elicited plasma from mice, non-human primates, and humans will be performed. Additionally, the lab will perform viral passaging experiments under pressure from human convalescent plasma following infection of mice, non-human primate, or human plasma following vaccination.
    - All of the required trainings have been completed for personnel completing this work.
    - Inactivation verification will be submitted per IBC protocol once work begins.
    - A SARS-CoV-2 medical management plan is in place for the BSL-3 program for occupational health requirements. Lab personnel need medical counseling before starting work with new biological agents.
    - The draft BUA letter was shown.
    - A member made a motion to approve the draft BUA letter for Dr. Veessler. Another member seconded the motion.
    - The Committee voted unanimously to approve the draft BUA for Dr. Veessler.
4. **ISSUES FROM THE FLOOR & PUBLIC COMMENTS:** There were no issues from the floor, and no public comments.
5. **MEETING ADJOURNED AT APPROXIMATELY 10:31 A.M.**